Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

81 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Tumor necrosis factor receptor-associated factor 1 (TRAF1) deficiency attenuates atherosclerosis in mice by impairing monocyte recruitment to the vessel wall.
Missiou A, Köstlin N, Varo N, Rudolf P, Aichele P, Ernst S, Münkel C, Walter C, Stachon P, Sommer B, Pfeifer D, Zirlik K, MacFarlane L, Wolf D, Tsitsikov E, Bode C, Libby P, Zirlik A. Missiou A, et al. Among authors: varo n. Circulation. 2010 May 11;121(18):2033-44. doi: 10.1161/CIRCULATIONAHA.109.895037. Epub 2010 Apr 26. Circulation. 2010. PMID: 20421522 Free PMC article.
Coinhibitory suppression of T cell activation by CD40 protects against obesity and adipose tissue inflammation in mice.
Wolf D, Jehle F, Michel NA, Bukosza EN, Rivera J, Chen YC, Hoppe N, Dufner B, Rodriguez AO, Colberg C, Nieto L, Rupprecht B, Wiedemann A, Schulte L, Peikert A, Bassler N, Lozhkin A, Hergeth SP, Stachon P, Hilgendorf I, Willecke F, von Zur Mühlen C, von Elverfeldt D, Binder CJ, Aichele P, Varo N, Febbraio MA, Libby P, Bode C, Peter K, Zirlik A. Wolf D, et al. Among authors: varo n. Circulation. 2014 Jun 10;129(23):2414-25. doi: 10.1161/CIRCULATIONAHA.113.008055. Epub 2014 Mar 24. Circulation. 2014. PMID: 24664276
TRAF5 deficiency accelerates atherogenesis in mice by increasing inflammatory cell recruitment and foam cell formation.
Missiou A, Rudolf P, Stachon P, Wolf D, Varo N, Aichele P, Colberg C, Hoppe N, Ernst S, Münkel C, Walter C, Sommer B, Hilgendorf I, Nakano H, Bode C, Zirlik A. Missiou A, et al. Among authors: varo n. Circ Res. 2010 Sep 17;107(6):757-66. doi: 10.1161/CIRCRESAHA.110.219295. Epub 2010 Jul 22. Circ Res. 2010. PMID: 20651286 Clinical Trial.
Soluble CD40L and cardiovascular risk in women.
Schönbeck U, Varo N, Libby P, Buring J, Ridker PM. Schönbeck U, et al. Among authors: varo n. Circulation. 2001 Nov 6;104(19):2266-8. doi: 10.1161/hc4401.099447. Circulation. 2001. PMID: 11696462
Soluble CD40L: risk prediction after acute coronary syndromes.
Varo N, de Lemos JA, Libby P, Morrow DA, Murphy SA, Nuzzo R, Gibson CM, Cannon CP, Braunwald E, Schönbeck U. Varo N, et al. Circulation. 2003 Sep 2;108(9):1049-52. doi: 10.1161/01.CIR.0000088521.04017.13. Epub 2003 Aug 11. Circulation. 2003. PMID: 12912804
Elevated plasma levels of the atherogenic mediator soluble CD40 ligand in diabetic patients: a novel target of thiazolidinediones.
Varo N, Vicent D, Libby P, Nuzzo R, Calle-Pascual AL, Bernal MR, Fernández-Cruz A, Veves A, Jarolim P, Varo JJ, Goldfine A, Horton E, Schönbeck U. Varo N, et al. Among authors: varo jj. Circulation. 2003 Jun 3;107(21):2664-9. doi: 10.1161/01.CIR.0000074043.46437.44. Epub 2003 May 12. Circulation. 2003. PMID: 12742991 Clinical Trial.
81 results